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1 To date, the consensus document has consolidated the PV isolation as the cornerstone of the AF ablation.
Although agreement has been reached that circumferential PV ablation to the endpoint of electric isolation is of great importance for the maintainance of sinus rhythm after ablation, the ablation strategy of solely targeting the PVs has touched the "ceiling" of success rate in the passing 5 years. Owing to the unsatisfying outcome for the sinus rhythm maintenance, the AF ablation has evolved into a "PVs + x" strategy, in which the "x" stands for either "non-PV triggering foci ablation," "rotor ablation" or "personalized substrate ablation."
The varied strategies beyond the circumferential PV isolation (CPVI) suggest the fact that the mechanism of AF is far from clear.
How AF is initiated and maintained remains to be elucidated. The current CPVI strategy was developed based on the observation that ectopic premature beats from the PVs initiating AF.
To date, beyond the CPVI, none of the "x" strategies has strongly proved its additional benefit for the AF ablation. This embarrassing situation may be due to the following reasons. First, the mechanism of AF is not fully understood. The theories on which the "x" strategy based might only touch one part of the truth for AF, consequently, the strategy itself can hardly demonstrate its benefit at the base of PV ablation. Second, the benefit of a certain kind of "x" approach performed to all the patients may be diluted by the different subgroups. That is to say, in a special subgroup of patients, a leading mechanism may play a more important role than the others. As a result, it may be more reasonable to apply an electrophysiologically based approach to a certain subgroup of patients.
In this direction, one step has just been attempted in the study performed by Masamichi et al 2 In this study, the investigators hy- proved that right heart disease produces a substrate for AF maintenance due to RA re-entrant activity, with an underlying substrate prominently involving RA fibrosis and conduction abnormalities. The study by Masamichi et al provided some clinical clues of a subgroup with "right AF" which warrants a special ablation strategy.
However, it still lacks convincing proof. To address this issue, several works remain to be done. First, the investigators should better explore whether there is a different substrate (especially right atrial substrate) between those patients with and without "normal" left atria. Second, it may be of special significance to investigate the genetic characteristics of those AF patients with the background of "normal" left atrium. Last, not the least, it is important to develop the tailored strategy targeting the right atrial substrate beyond the PVs in this presumed subset of patients.
Although catheter ablation has been an established therapeutic strategy for AF for more than two decades, the recurrence of atrial arrhythmias after ablation is common. How to further improve the outcome seems to be crucially important in clinical research.
